MP71-11 URINARY SYMPTOMS AND MEDICATIONS USED IN MEN ATTENDING A NATIONAL HEALTH SCREENING PROGRAM

Abstract

You have accessJournal of UrologyBenign Prostatic Hyperplasia: Evaluation and Symptoms1 Apr 2015MP71-11 URINARY SYMPTOMS AND MEDICATIONS USED IN MEN ATTENDING A NATIONAL HEALTH SCREENING PROGRAM Nelson Stone, Wendy Poage, and E. David Crawford Nelson StoneNelson Stone More articles by this author , Wendy PoageWendy Poage More articles by this author , and E. David CrawfordE. David Crawford More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2624AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To identify which patient factors are associated with urinary symptom (AUASS) and nocturia severity (NoctSS) and the use of urinary medication in men attending a national health screening program. METHODS 3277 men with a median age of 63 years (IQ 56-69) participated in Prostate Cancer Awareness Week in 2013 and had testosterone (T), prostate specific antigen (PSA), cholesterol (Chol) determinations and completed an extensive screening questionnaire which included life style habits, coexisting diseases, body mass index (BMI), medication (UMED) use and prostate size (BPH) by digital rectal exam. Significant associations were determined by test for variance (ANOVA) for mean T, PSA, Chol and by chi-square (Pearson) for hypogonadal state (T<300 ng/dL), AUASS and NoctSS (0-7, 0-1 minimal-1, 8-19, 2-3 moderate-2, and 20-35, 4-5 severe-3) and medication use. The effect of multiple variables on AUASS and NoctSS were determined by linear regression. RESULTS AUASS and NoctSS were 1: 62.7% and 48.7%, 2: 30.8% and 40.3%, and 3: 6.4% and 11%, respectively. Median PSA was 1.11 ng/ml (IQ 0.62-2.2). AUASS and NoctSS were increased with older age (p<0.001), presence of BPH (p<0.001), HBP (p=0.026), smoking (p=0.001), increased fat intake (p=0.008), and high PSA (p<0.001), respectively. Increased BMI, presence of diabetes, low T or high Chol were not associated with increased symptoms. A history of prostatitis (n=185, 5.9%) was highly associated with AUASS (p<0.001, 12.4% vs 6.1%) but not for nocturia. Linear regression revealed age (p=0.001), PSA (p=0.041). BPH (p<0.001, HR 1.196, 95%CI 0.809-1.583) and prostatitis (p<0.001, HR 2.963, 95% CI 1.531-4.394) as significant for AUASS. For NoctSS age (p=0.001) and BPH (p=0.004) were significant. UMED was reported in 264 (8.4%) and was used 5x and 3.2x more frequently in men with AUASS, and NoctSS 2 and 3, respectively (p<0.001). However, in men with AUASS3 and NoctSS3, 72.4% and 89.05 (p<0.001) did not use UMED. CONCLUSIONS The incidence of moderate to severe urinary symptoms in a screened male population is substantial. 11% of men have nocturia 4-5x/night. An enlarged prostate by DRE and PSA > 2 ng/ml are associated with moderate to severe urinary symptoms and nocturia. A history of prostatitis increases the risk of AUASS by 3-fold. While UMED is utilized more often in symptomatic men, almost 90% of those with severe nocturia are not taking any medication. These data should assist physicians in identifying men with urinary symptoms and warrant further investigation as to why UMED usage is so limited in the most symptomatic individuals. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e915-e916 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Nelson Stone More articles by this author Wendy Poage More articles by this author E. David Crawford More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...